Pharmaceuticals

Takeda Pharmaceutical Company

Takeda Pharmaceutical evaluating provision amount for fiscal year ending March 31, 2026

Takeda Reports Quarterly Earnings: Revenue and Profit Significantly Beat Estimates, Announces Dividend Hike and Cost-Saving Targets

Takeda Pharmaceutical Company released FY2026 earnings on May 13 Pre-Market (EST), actual revenue USD 29.69 B (forecast USD 28.38 B), actual EPS USD 0.3941 (forecast USD 0.3081)

Takeda Pharmaceutical Company released FY2026 Q4 earnings on May 13 Pre-Market EST, actual revenue USD 6.854 B (forecast USD 6.998 B), actual EPS USD -0.0483

Takeda Pharmaceutical Company to Release FY2026 Earnings on May 13 Pre-Market EST, Forecast Revenue USD 28.85 B, EPS USD 0.3357

Takeda's TYK2 inhibitor shows positive results in phase III clinical trials for psoriasis

Takeda Pharmaceutical Plans FDA Submission for Psoriasis Drug Zasocitinib

Takeda's New Drug Application Granted Priority Review by FDA

Iambic and Takeda Sign $1.7B Partnership for AI-Driven Cancer Drug Development

Takeda Pharmaceutical Company released FY2026 9 Months earnings on January 29 After-Market EST, actual revenue USD 15.13 B, actual EPS USD 0.245

Takeda Pharmaceutical Company released FY2026 Q3 earnings on January 29 After-Market EST, actual revenue USD 7.616 B (forecast USD 7.68 B), actual EPS USD 0.2063

Takeda Pharmaceutical Co - ADR 2026 EPS Forecast Revised Down to 0.32

FactSet: Takeda Pharmaceutical Co - ADR Target Price Raised

Takeda Pharmaceutical Company to Release FY2026 Q3 Earnings on January 29 After-Market EST, Forecast Revenue USD 7.548 B

Positive Zasocitinib Clinical Trial Data from Takeda Catalyzes New Era in Psoriasis Treatment

Takeda Publishes New Data on Mezagitamab for IgA Nephropathy

Takeda Pharmaceutical Company released FY2026 Q2 earnings on October 30, 2025, after-market EST: Actual Revenue USD 7.487 B (Forecast USD 7.97 B), Actual EPS USD -0.0251

Takeda Pharmaceutical Company released FY2026 Semi-Annual Earnings on October 30 After-Market EST, actual revenue USD 15.13 B (forecast USD 15.48 B), actual EPS USD 0.2401

Takeda Pharmaceutical Sees 40% Drop in Net Profit in First Half of 2023

Takeda Pharmaceutical Company to Release FY2026 Q2 Earnings on October 30 After-Market EST, Forecast Revenue USD 7.757 B

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Takeda Pharmaceutical Co. Ltd.

Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict

4502

Takeda Pharmaceutical faces an $885 million jury verdict in an antitrust case related to its drug Amitiza. The jury found that a 2014 settlement delayed competition, violating antitrust laws. Takeda plans to appeal, asserting the settlement was lawful and allowed for an authorized generic launch. The damages awarded will triple under U.S. law, with further proceedings pending for additional claims. Takeda's stock rose slightly, but the company has seen a decline over the past month.

benzinga_article

S&P 500

Jury Hits Takeda With $885 Million Antitrust Verdict

Takeda Pharmaceutical Co. Ltd. has been ordered to pay $884.9 million in damages following a jury verdict in an antitrust case related to its AMITIZA drug. The company plans to appeal the decision and will revise its FY25 financial results, although it does not expect a significant impact on its core financials for FY25 or FY26. Takeda's stock closed at $16.57, slightly down, but traded higher in after-hours.

rttnews

Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results

Takeda Pharmaceutical Co faces a significant antitrust verdict regarding its constipation drug AMITIZA, with a Massachusetts jury awarding nearly USD 885 million in damages. The company disputes the ruling and plans to recognize a provision in its FY2025 results, although it expects no impact on core figures. Takeda may revise its FY2026 outlook based on further assessments. The current analyst rating for Takeda stock is a Buy with a price target of Yen6900.00.

Tip Ranks

Takeda faces major AMITIZA antitrust verdict and prepares FY2025 provision

Attorneys at Hagens Berman announced a $474.89 million jury verdict against Takeda Pharmaceuticals in a class-action lawsuit over Amitiza. The jury found Takeda liable for antitrust violations related to delaying the launch of a generic version of the drug, resulting in overcharges to consumers. The total damages, including statutory trebling, amount to $1.4 billion. The trial highlighted a pay-for-delay scheme that harmed competition and the healthcare system.

MorningStar

PAR Tech

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda

Takeda Pharmaceutical Company(TAK.US)

Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict

Jury Hits Takeda With $885 Million Antitrust Verdict

Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results

Takeda faces major AMITIZA antitrust verdict and prepares FY2025 provision

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda